Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA6 | P23280 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | TPMT | P51580 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976822 | 0.87 | CA12 (0.67) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL17040779 | 0.86 | LMNA (0.56) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL6169559 | 0.81 | HTT (0.62) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL18361967 | 0.81 | HTT (0.42) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL4338424 | 0.80 | TTR (0.50) | HTTLMNAMAPK1RAB9ACA12 | |
| SCHEMBL18031512 | 0.80 | HTT (0.61) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL15197099 | 0.80 | CA12 (0.58) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL30808277 | 0.80 | CA12 (0.58) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL21821412 | 0.80 | CA12 (0.58) | HTTLMNAMAPK1RAB9APTGS2 | |
| SCHEMBL2286383 | 0.80 | PTGS2 (0.76) | HTTLMNAMAPK1RAB9APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119731179-A | IKZF2 degradation agent and application thereof | 密歇根大学董事会 | 2025-03-28 | — | — | CN | disclosed |
| EP-4499649-A1 | IKZF2 DEGRADERS AND USES THEREOF | Regents of the University of Michigan (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023183540-A1 | IKZF2 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| EP-3313834-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017003995-A1 | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017003995-A1 | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | IKZF1, IKZF2, IKZF3 | HTT 3561/4885LMNA 2571/4885MAPK1 4385/4885 |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | HTT 4197/4885LMNA 2057/4885MAPK1 295/4885 |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | HTT 4197/4885LMNA 2057/4885MAPK1 295/4885 |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | HTT 4197/4885LMNA 2057/4885MAPK1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.